| Oct 29 |
Exelixis (EXEL) Q3 Earnings and Revenues Beat Estimates
|
| Oct 29 |
Exelixis raises 2024 revenue guidance as Q3 beats on both lines
|
| Oct 29 |
Exelixis: Q3 Earnings Snapshot
|
| Oct 29 |
Exelixis Non-GAAP EPS of $0.47 beats by $0.05, revenue of $539.5M beats by $49.19M
|
| Oct 29 |
Exelixis Announces Third Quarter 2024 Financial Results and Provides Corporate Update
|
| Oct 28 |
Exelixis Q3 2024 Earnings Preview
|
| Oct 25 |
Zacks Industry Outlook Highlights Exelixis, Blueprint Medicines, CRISPR, Amicus and Verona Pharma
|
| Oct 24 |
5 Biotech Stocks Likely to Outperform as Industry Prospects Look Bright
|
| Oct 23 |
Here's Why Exelixis (EXEL) is a Great Momentum Stock to Buy
|
| Oct 23 |
Intra-Cellular Therapies (ITCI) Expected to Beat Earnings Estimates: Should You Buy?
|
